Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer
- Vedder, M.M. (Moniek)
- Márquez, M. (Mirari)
- Bekker-Grob, E.W. (Esther) de
- Calle, M.L. (Malu)
- Dyrskjot, L. (Lars)
- Kogevinas, M. (Manolis)
- Segersten, U. (Ulrika)
- Malmström, P.-U. (Per-Uno)
- Algaba, F. (Ferran)
- Beukers, W. (Willemien)
- Orntoft, T.F. (Torben)
- Zwarthoff, E.C. (Ellen)
- Real, F.X. (Francisco)
- Malats, N. (Núria)
- Steyerberg, E.W. (Ewout)
DOIAbstract
Objective: We aimed to determine the validity of two risk scores for patients with non-muscle invasive bladder cancer in different European settings, in patients with primary tumours. Methods: We included 1,892 patients with primary stage Ta or T1 non-muscle invasive bladder cancer who underwent a transurethral resection in Spain (n = 973), the Netherlands (n = 639), or Denmark (n = 280). We evaluated recurrence-free survival and progression-free survival according to the European Organisation for Research
Add to ORKG